EUCTR2007-007604-15-GB进行中（未招募）1 期
A Pilot Study of the Effect of Glucocorticoid Receptor Antagonism in Patients with Sub-Clinical Cushing's Syndrome - Glucocorticoid Receptor Antagonism in Sub-Clinical Cushings
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •- male and over 18 years old or postmenopausal women
- •- Patients have adrenal incidentaloma with benign characteristics as assessed on CT or MRI
- •- Patients lack clinical features classically associated with Cushing's Syndrome
- •- Patients have evidence of excess cortisol as shown by lack of supression of serum cortisol using standard routine tests
- •- Patients are on stable antihypertensive and diabetic medication for two months prior to study entry
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion criteria include:
- •- evidence of local or systemic malignancy
- •- overt Cushing's Syndrome
- •- servere uncontrolled diabetes mellitus or hypertension
- •- pregnancy
- •- clinically significantly impaired cardiovascular function, severe liver disease, significantly impaired renal function
- •- uncontrolled severe active infection
- •- treatment with approved or experimental drugs which work on the adrenal glands
- •- in women a known history of uterine problems
- •- a requirement for steroids for existing disease
- •- impaired mental capacity or markedly abnormal psychiatric evaluation that precludes informed consent
研究者
相似试验
已完成
1 期
Glucocorticoid Receptor Antagonism in Subclinical CushingsSubclinical Cushing'sNCT00721201Sheffield Teaching Hospitals NHS Foundation Trust6
已完成
不适用
A pilot study on prevention of glucocorticoid induced diabetes mellitus by linagliptiPatients scheduled administration of glucocorticoidJPRN-UMIN000015588Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.17
进行中（未招募）
1 期
A study to assess whether a product call relacorilant works and is safe to use in patients with Cushing Syndrome; some patients will receive relacorilant whilst others receive a placebo.Endogenous Cushing syndromeMedDRA version: 20.0 Level: LLT Classification code 10011657 Term: Cushings syndrome System Organ Class: 100000004860EUCTR2018-003096-35-ESCorcept Therapeutics Incorporated130
进行中（未招募）
1 期
A study to assess whether a product called relacorilant works and is safe to use in patients with Cushing Syndrome; some patients will receive relacorilant whilst others receive a placebo.EUCTR2018-003096-35-DECorcept Therapeutics Incorporated145
进行中（未招募）
1 期
A study to assess whether relacorilant works and is safe to use in patients with Hypercortisolism due to Cortisol-Secreting Adrenal Adenomas or Hyperplasia; some patients will receive relacorilant whilst others receive a placebo.hypercortisolismMedDRA version: 22.1Level: LLTClassification code 10020611Term: HypercortisolismSystem Organ Class: 100000004860EUCTR2019-004956-12-ITCORCEPT THERAPEUTICS130